Biotricity INC

Biotricity Inc. has entered into exchange agreements to convert existing common stock, options, and warrants into newly created Series C Preferred Stock.

Biotricity Inc. announced strong second quarter fiscal 2026 financial results, showcasing significant revenue growth, improved gross margins, and a substantial reduction in net loss, driven by operational efficiencies and strategic market expansion.

Biotricity announces strong Q3 fiscal year 2025 results, featuring record margins, revenues, and cash flows, driven by a 21.7% year-over-year sales increase.

Biotricity announced a 13% year-over-year revenue increase and significant margin improvements for the second quarter of fiscal year 2025, achieving positive cash flow in September on a current operating basis.

Biotricity Inc. held its annual meeting, electing four directors and ratifying its auditor, but rejecting a proposal for a stock issuance related to convertible preferred stock.

Biotricity Inc. has received notice of delisting from the Nasdaq Capital Market due to failure to maintain the minimum market value of listed securities, with trading suspended on August 5, 2024.

Biotricity Inc. reported significant revenue growth and improved operating profit for the nine months ended December 31, 2025, despite ongoing net losses and working capital challenges.

Biotricity Inc. announced significant revenue growth and a second consecutive quarter of positive operating profit, despite ongoing liquidity concerns and a substantial accumulated deficit.

Biotricity Inc. reported its first-ever positive profit from operations and fourth consecutive quarter of positive free cash flow, driven by strong revenue growth and improved gross margins.

Biotricity Inc. files an amended quarterly report to correct clerical errors, while still facing substantial doubt about its ability to continue as a going concern.

Biotricity Inc. announces revenue growth and reduced operating expenses for the quarter ended December 31, 2024, signaling progress towards profitability.

Biotricity Inc. announced a 9.4% year-over-year increase in revenue for the six months ended September 30, 2024, alongside significant improvements in gross margin and operating expense management.

Biotricity Inc. announced its fiscal year 2026 results, showing revenue growth and a reduced net loss, while highlighting ongoing product development and market expansion.

Biotricity Inc. filed an amended annual report for fiscal year 2025, showcasing increased revenue and improved gross profit, while still facing significant accumulated deficits and a going concern qualification from its auditors following its delisting from Nasdaq.

Biotricity, a medical technology company, reported increased revenue and gross profit for fiscal year 2025, alongside a positive Adjusted EBITDA for the fourth quarter, despite continued net losses and an auditor's 'going concern' warning.

Biotricity Inc. has refiled its annual report on Form 10-K/A to include the consent of its independent registered public accounting firm, SRCO Professional Corporation.

Biotricity Inc.'s annual 10-K filing outlines the company's share structure, financial performance, and strategic direction in the medical technology sector.

Biotricity Inc. is holding its annual meeting of stockholders on August 15, 2024, to vote on the election of directors, ratification of its accounting firm, approval of a potential equity issuance, and an adjournment proposal.

Biotricity Inc. is soliciting proxies for its annual shareholder meeting on August 15, 2024, covering director elections, auditor ratification, and approval for a common stock issuance upon conversion of preferred stock.

Biotricity Inc. is seeking stockholder approval to issue securities in one or more non-public offerings to raise up to $20 million for general corporate purposes.

Biotricity Inc. files S-1, detailing expansion in cardiac monitoring solutions and AI development, alongside significant financial challenges including recurring losses and going concern doubt.

Biotricity is seeking to raise capital through a best efforts offering of common stock and pre-funded warrants to support working capital and general corporate purposes.

Ionic Ventures LLC and affiliated entities have updated their Schedule 13G filing to report beneficial ownership of 3,096,987 shares of BioTricity Inc. common stock, representing 9.9% of the outstanding shares.

Ionic Ventures and its affiliates updated their beneficial ownership in Biotricity Inc. to 9.99% of common stock, including convertible preferred shares.

Ionic Ventures and its affiliates disclose a 9.9% beneficial ownership stake in Biotricity Inc., totaling 2,839,930 shares, including common and convertible preferred stock.

Ionic Ventures, LLC and its affiliated reporting persons have filed an Amendment No. 3 to their Schedule 13G, reaffirming their beneficial ownership of 9.9% of Biotricity Inc.'s common stock, subject to a 9.99% beneficial ownership limitation on preferred stock conversions.

Ionic Ventures, LLC and its affiliates have filed an amended Schedule 13G, updating their beneficial ownership in Biotricity Inc. to 9.9% of the common stock, reflecting holdings of common stock and convertible preferred stock subject to a 9.99% ownership limitation.